Longitudinal Data
longitudinal data
Learning through the eyes and ears of a child
Young children have sophisticated representations of their visual and linguistic environment. Where do these representations come from? How much knowledge arises through generic learning mechanisms applied to sensory data, and how much requires more substantive (possibly innate) inductive biases? We examine these questions by training neural networks solely on longitudinal data collected from a single child (Sullivan et al., 2020), consisting of egocentric video and audio streams. Our principal findings are as follows: 1) Based on visual only training, neural networks can acquire high-level visual features that are broadly useful across categorization and segmentation tasks. 2) Based on language only training, networks can acquire meaningful clusters of words and sentence-level syntactic sensitivity. 3) Based on paired visual and language training, networks can acquire word-referent mappings from tens of noisy examples and align their multi-modal conceptual systems. Taken together, our results show how sophisticated visual and linguistic representations can arise through data-driven learning applied to one child’s first-person experience.
When to stop immune checkpoint inhibitor for malignant melanoma? Challenges in emulating target trials
Observational data have become a popular source of evidence for causal effects when no randomized controlled trial exists, or to supplement information provided by those. In practice, a wide range of designs and analytical choices exist, and one recent approach relies on the target trial emulation framework. This framework is particularly well suited to mimic what could be obtained in a specific randomized controlled trial, while avoiding time-related selection biases. In this abstract, we present how this framework could be useful to emulate trials in malignant melanoma, and the challenges faced when planning such a study using longitudinal observational data from a cohort study. More specifically, two questions are envisaged: duration of immune checkpoint inhibitors, and trials comparing treatment strategies for BRAF V600-mutant patients (targeted therapy as 1st line, followed by immunotherapy as 2nd line, vs. immunotherapy as 2nd line followed by targeted therapy as 1st line). Using data from 1027 participants to the MELBASE cohort, we detail the results for the emulation of a trial where immune checkpoint inhibitor would be stopped at 6 months vs. continued, in patients in response or with stable disease.